University Hospital, Lille: Parkinson Disease trials

The registry lists 17 Parkinson Disease studies with University Hospital, Lille as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 4Phase 3 2Phase 4 2No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of a New Communication Aid Tool to Favor Global Patient Centered CareRecruitingNCT04179695Not applicable
• Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)CompletedNCT07214285Phase 1/2
• Markers of Disease Progression and Gait Within the Parkinsonian PopulationCompletedNCT04653688Not applicable
• Education for Adapted Physical Activity in Parkinson's DiseaseCompletedNCT04340492Not applicable
• Dopaminergic restauratIon by intraVEntriculaire AdministrationCompletedNCT04332276Phase 1/2
• Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's DiseaseCompletedNCT04259203Not applicable
• Identification of Risk Factors Parkinson's Disease by Convergence StrategyCompletedNCT03536104
• Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's DiseaseCompletedNCT03517059
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable
• Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedNCT02655315Phase 2
• Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's DiseaseCompletedNCT02627664
• Predictive Factors and Subthalamic Stimulation in Parkinson's DiseaseCompletedNCT02360683
• Cognitive Phenotypes in Parkinson's DiseaseCompletedNCT01792843
• Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's DiseaseCompletedNCT01108029Phase 4
• Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT00943748Phase 2/3
• Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)CompletedNCT00914095Phase 4
• Study of Rivastigmine to Treat Parkinsonian Apathy Without DementiaCompletedNCT00767091Phase 3